Drug intelligence / Profile preview

colistin + cyclosporine + polymyxin B + prednisolone

Development stage: Unknown
Lead developer: Sandoz
Modality: Small Molecules
Administration: Topical, Ophthalmic

Overview

A combination drug containing two polymyxin antibiotics (colistin and polymyxin B), an immunosuppressant (cyclosporine), and a corticosteroid (prednisolone). This combination likely targets multidrug-resistant gram-negative bacterial infections while providing anti-inflammatory and immunomodulatory effects. The polymyxins disrupt bacterial cell membranes by binding to lipopolysaccharides, increasing membrane permeability and causing cell death. Cyclosporine acts as an immunosuppressant, while prednisolone provides anti-inflammatory effects.

Targets

Cyp (Cyclophilin family)GR (Glucocorticoid receptor)CN (Calcineurin)

Beyond the preview

Go deeper on colistin + cyclosporine + polymyxin B + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on colistin + cyclosporine + polymyxin B + prednisolone.

Explore the full profile